Drug intelligence / Profile preview

IVIg-SN 10%

Development stage
Phase 4
Lead developer
GC Biopharma
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

IVIg-SN 10% is a modern intravenous immunoglobulin (IVIG) product formulated as a sterile, highly purified, concentrated solution containing human immunoglobulin G (IgG) at a concentration of 10%. It is derived from pooled plasma collected from healthy donors and undergoes multiple pathogen elimination steps to ensure safety. The primary mechanism of action is passive immunity—supplying exogenous IgG antibodies that neutralize pathogens and modulate immune responses. This product is indicated for the prevention of infections in patients with primary immunodeficiency (PID), among other uses typical for IVIG products such as immune thrombocytopenic purpura and Kawasaki syndrome. Clinical studies have demonstrated that IVIg-SN 10% effectively maintains protective IgG levels in PID patients, reduces infection rates, and has a favorable safety profile with mostly mild adverse events[5][7].

Brand names
IVIg-SN 10%
Other names
intravenous immunoglobulin SN 10%human immunoglobulin G SN 10%
02

Targets

FASN (Fatty acid synthase)C3b (Complement Component 3b)CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on IVIg-SN 10%.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVIg-SN 10%.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call